Most importantly, however, clinical and mouse studies have reported increased plasma FGF21 concentration in patients and animal models of MASLD, and thus FGF21 has been proposed as a marker of liver steatosis (57–60). The gene discussed is FGF21; the disease is fatty liver disease.